Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
RFK Jr.’s peptide policy could boost Hims & Hers as its GLP-1 business evolves
– Advertisement –
Broadcom stock plunges 11% on weak software sales, unchanged AI chip forecast for the year 
SpaceX wins tax exemption for $55bn AI chip plant despite local backlash 
Crypto correction vaporized $176B in investor funds: Are bears back in control? 
